CDC panel OKs Pfizer booster for 65 and older, others at high risk

An advisory panel for the U.S. Centers for Disease Control and Prevention granted its final approval on Thursday for offering booster doses of Pfizer’s COVID-19 vaccine to Americans ages 65 and up and others at high risk for severe disease, clearing the way for the extra shots to begin.